These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 1380082

  • 1. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.
    Bowden CR, Voina SJ, Woestenborghs R, De Coster R, Heykants J.
    J Pharmacol Exp Ther; 1992 Aug; 262(2):699-706. PubMed ID: 1380082
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
    Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA.
    Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
    [Abstract] [Full Text] [Related]

  • 3. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE, Janssen PM, Megens AA, Schotte A.
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [Abstract] [Full Text] [Related]

  • 4. Biochemical profile of risperidone, a new antipsychotic.
    Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA.
    J Pharmacol Exp Ther; 1988 Nov; 247(2):661-70. PubMed ID: 2460616
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA, Awouters FH, Meert TF, Schellekens KH, Niemegeers CJ, Janssen PA.
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [Abstract] [Full Text] [Related]

  • 6. Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol.
    Megens AA, Niemegeers CJ, Awouters FH.
    J Pharmacol Exp Ther; 1992 Jan; 260(1):160-7. PubMed ID: 1370539
    [Abstract] [Full Text] [Related]

  • 7. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF.
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [Abstract] [Full Text] [Related]

  • 8. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.
    Awouters F, Niemegeers CJ, Megens AA, Janssen PA.
    J Pharmacol Exp Ther; 1990 Sep; 254(3):945-51. PubMed ID: 1697623
    [Abstract] [Full Text] [Related]

  • 9. Effect of ergovaline, loline, and dopamine antagonists on rat pituitary cell prolactin release in vitro.
    Strickland JR, Cross DL, Birrenkott GP, Grimes LW.
    Am J Vet Res; 1994 May; 55(5):716-21. PubMed ID: 8067623
    [Abstract] [Full Text] [Related]

  • 10. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
    Janssen PA, Awouters FH.
    Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
    [Abstract] [Full Text] [Related]

  • 11. Risperidone.
    Cohen LJ.
    Pharmacotherapy; 1994 Mar; 14(3):253-65. PubMed ID: 7524043
    [Abstract] [Full Text] [Related]

  • 12. Metabolites of an antipsychotic chiral pyrroloisoquinoline and their effect on prolactin secretion in the rat.
    Kolis SJ, Williams TH, Mowles TF, Burghardt B, Toome V, Schwartz MA.
    J Pharmacol Exp Ther; 1983 Dec; 227(3):652-7. PubMed ID: 6140308
    [Abstract] [Full Text] [Related]

  • 13. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
    Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM.
    Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
    [Abstract] [Full Text] [Related]

  • 14. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland.
    Inoue T, Domae M, Yamada K, Furukawa T.
    J Pharmacol Exp Ther; 1996 Apr; 277(1):137-43. PubMed ID: 8613910
    [Abstract] [Full Text] [Related]

  • 15. Survey on the pharmacodynamics of the new antipsychotic risperidone.
    Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE.
    Psychopharmacology (Berl); 1994 Feb; 114(1):9-23. PubMed ID: 7531353
    [Abstract] [Full Text] [Related]

  • 16. Prolactin releasing potencies of antipsychotic and related nonantipsychotic compounds in female rats: relation to clinical potencies.
    Hays SE, Poland RE, Rubin RT.
    J Pharmacol Exp Ther; 1980 Aug; 214(2):362-7. PubMed ID: 6104725
    [Abstract] [Full Text] [Related]

  • 17. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
    Schotte A, Janssen PF, Megens AA, Leysen JE.
    Brain Res; 1993 Dec 24; 631(2):191-202. PubMed ID: 7510574
    [Abstract] [Full Text] [Related]

  • 18. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.
    Pharmacol Biochem Behav; 2005 Oct 24; 82(2):361-72. PubMed ID: 16216322
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.